Myriad of Groups Are Working on the Latest Hot Target and Most Are Optimistic About Its Potential Although the term “signal transduction” was coined back in 1972, cell-signaling switches have only ...

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...

Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...

SAN FRANCISCO -- In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) recurrence, according to a randomized study reported here.

Pretreatment tumor was evaluated from operable TNBC patients enrolled on a clinical trial of neoadjuvant therapy (NAT; A Robust TNBC Evaluation fraMework to Improve Survival [ClinicalTrials.gov ...

Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...

A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research ...

CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly improved survival in advanced breast cancer patients with PIK3CA-mutated, ...